Bergen Pursues Legislative, Managerial Remedies for PharMerica
Executive Summary
Reimbursement pressure on Bergen Brunswig's PharMerica long-term care pharmacy business is prompting the parent company to lobby for changes to Medicare's Prospective Payment System.
You may also be interested in...
McKessonHBOC Gives Ex-CEO Pulido $17.5 Mil. Severance Package
McKessonHBOC is providing former CEO Mark Pulido with a severance package worth $17.5 mil.
McKessonHBOC Gives Ex-CEO Pulido $17.5 Mil. Severance Package
McKessonHBOC is providing former CEO Mark Pulido with a severance package worth $17.5 mil.
Bristol Glucophage Strategy Lifts Stock As Sector Wilts From Medicare Redux
Bristol-Myers Squibb's diabetes portfolio was a sweetener for the Street as the stock turned in one of the few positive showings among big pharma companies during a quarter marked by increasing political rhetoric over a Medicare drug benefit.